Breast Cancer | Disease Landscape and Forecast | G7 | 2021
Characterized by high incidence and long treatment durations, the breast cancer therapy market represents substantial commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios) are creating new dynamics in the treatment of metastatic HR-positive/HER2-negative disease. Meanwhile, novel HER2-targeted agents, label expansions, and biosimilar entries—all of which will lead to changes in treatment guidelines—will have an impact on sales of current drugs for HER2-positive breast cancer. Furthermore, the approval of PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza and Pfizer’s Talzenna), immune checkpoint inhibitors (Roche / Genentech / Chugai’s Tecentriq and Merck & Co.’s Keytruda), PI3K inhibitors (Novartis’s Piqray), HER2-targeted agents (Daiichi Sankyo / AstraZeneca’s Enhertu, Seagen / Pfizer’s Tukysa, and MacroGenics’ Margenza), and TROP2-targeted agents (Gilead’s Trodelvy), as well as the anticipated entry of other agents from these drug classes, will diversify treatment options, especially for triple-negative breast cancer.
What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?
What is the expected market impact of recent drug approvals, such as Keytruda, Piqray, Enhertu, and Tukysa, on the various subpopulations of breast cancer?
What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer therapy market?
What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Geographies: United States, EU5, Japan.
Primary research: 19 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other Clarivate research.
Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy.
Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2030, segmented by brands / biosimilars / generics and market-relevant drug-treatable populations.
Emerging therapies: Phase III/PR: 18 drugs; coverage of select Phase I and II products.